Disclosures for "Cilnidipine, a Novel N-Type Specific Calcium Channel Antagonist, Has Potent Activity at the Nav1.7 Sodium Channel, Which May Have Implications for Treatment of Certain Neuropathic Pain Conditions")
-
Dr. Sternlicht has received personal compensation for serving as an employee of Hotelrecovery, Inc. . Dr. Sternlicht has stock in Aisa Pharma. Dr. Sternlicht has received intellectual property interests from a discovery or technology relating to health care.